Skip to Content

Capgemini positioned as a Leader for Life Sciences Digital Services 2021 in Everest Group’s PEAK Matrix®

06 Jul 2022

Capgemini announced today that it has been named a Leader by Everest Group in its Life Sciences Digital Services PEAK Matrix® Assessment 2021. Capgemini was recognized as a Leader for its vision and capability and ability to create market impact among 27 IT service providers evaluated by Everest Group for this assessment.

“As the life sciences industry starts to recover from the pandemic, a key challenge for enterprises will be scaling up digital initiatives and adopting a long-term digital transformation strategy,” said Chunky Satija, Practice Director, Everest Group. “Capgemini has ramped up its capabilities, building IP and accelerators to support enterprises in developing their long-term digital strategies. The Altran acquisition and recently released Intelligent Industry offerings for life sciences have strengthened its capabilities in drug discovery, clinical and pre-clinical trials, and manufacturing, helping to position Capgemini as a Leader on Everest Group’s Life Sciences Digital Services PEAK Matrix® Assessment 2021.”

Olivier Zitoun, Global Head of Life Sciences at Capgemini said, “We are proud to be recognized by Everest Group as a Leader for Life Sciences Digital Services. This recognition is testament to Capgemini’s data-driven approach to life sciences, strengthened by our integration of Altran, which enables us to unlock the real value of R&D, foster innovation, leverage intelligent operations to create new customer experiences, and deliver new sources of value for our clients. By applying the potential of Intelligent Industry powered by data, we have the capabilities to design, develop, and deliver best-in-class products and solutions at speed and scale.” 

As part of the leader positioning, Everest Group cited Capgemini’s strengths, including the Altran acquisition which has reinforced Capgemini’s capabilities in drug discovery (AI studio for data-driven R&D, genomic data analytics), clinical and preclinical trials, and manufacturing value chain (Intelligent Industry set of offerings for life-sciences); a well-rounded portfolio of vertical specific partnerships and in-house tools/accelerators to enable the rapid design and development of customized data-driven solutions; strong domain understanding supplemented with focused investments in innovation and thought leadership through a life-sciences specific CoE; and significant presence in both North America and Europe.

Click here to access a custom version of the report.